{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pityriasis-rosea/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"67565f4b-e371-5339-8d04-8fb65cb26c28","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ab82b4e4-063b-4ecd-a342-e4eab601274a --><h2>Changes</h2><!-- end field ab82b4e4-063b-4ecd-a342-e4eab601274a -->","summary":null,"htmlStringContent":"<!-- begin item 6b2adec0-c6df-47e9-8f2b-672dc6c7ec36 --><!-- begin field c4971bfc-1186-4ae6-96d9-3223fc7ab1e5 --><p><strong>April 2020 </strong>— reviewed. A literature search was conducted in February 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.</p><!-- end field c4971bfc-1186-4ae6-96d9-3223fc7ab1e5 --><!-- end item 6b2adec0-c6df-47e9-8f2b-672dc6c7ec36 -->","topic":{"id":"c96d68c3-bb0b-5b8c-b256-6b3e415d7ab2","topicId":"76763692-46bc-4f1e-add3-6c012ccd584a","topicName":"Pityriasis rosea","slug":"pityriasis-rosea","lastRevised":"Last revised in April 2020","chapters":[{"id":"82c04d82-7b6f-594a-8190-44f70c341f1b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b21af5b-81ad-5b28-9df9-d6b7c4fdd3d4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"357337fc-eefc-5ff8-84bf-cc4e15f9a2da","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67565f4b-e371-5339-8d04-8fb65cb26c28","slug":"changes","fullItemName":"Changes"},{"id":"3b3d1372-8e27-5563-9a36-273677bd9a82","slug":"update","fullItemName":"Update"}]},{"id":"75f5c2f6-34b3-5b64-ab41-c7457b8eedd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26135976-eb67-5dd8-ad15-9a98086871b7","slug":"goals","fullItemName":"Goals"},{"id":"96f6df37-1ba4-5020-8435-cbeac8de1488","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"026de696-4951-5e10-a246-456d67c1fea8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"03d26d2a-90f8-53c5-97e9-cff9d95ae299","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87a8200e-6cd0-588d-8d4b-86117be364e6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ba1ef82b-8a8a-558d-a84a-552083dcd2e1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a8f04415-38ec-5eb9-8282-733c37db5bac","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"38f858f2-48f8-54e6-bb01-5b58106435cc","slug":"definition","fullItemName":"Definition"},{"id":"f7fffe58-e2a4-5913-8a5a-354aad8d52f0","slug":"causes","fullItemName":"Causes"},{"id":"090f1bfe-2513-53a8-ade3-e8368ec7d5d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"20025f23-bbb9-5095-9acc-da8d9e15840b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"72d63a33-0ca6-552f-81a8-200eef91d046","slug":"complications","fullItemName":"Complications"}]},{"id":"75dd0d1f-b162-54b6-b1ba-3833b13ae73e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"44c5742e-2d6e-5ce6-806a-03940c5572f8","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f2c8da26-1065-5bb2-add8-43b39f41b5fe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d71093b6-b130-5eeb-8e0f-443adf8be4aa","fullItemName":"Management","slug":"management","subChapters":[{"id":"0bc06d9c-42f1-5228-adf5-4eda9826e67a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c48f4302-0f7c-58d9-86ad-d5379d244e71","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"eee3f004-1425-502e-a455-287742b3ec77","slug":"emollients","fullItemName":"Emollients"},{"id":"51eb73bd-9e63-5028-815d-bf148fa863d9","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"186fab77-8c30-557b-bd7b-f756eb8f9cab","slug":"antihistamines","fullItemName":"Antihistamines"}]},{"id":"b3c2db78-1290-58fb-9bb3-3a5db8e45669","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e683b047-2b38-5f72-a4b8-c79a83946894","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2d6d1b8c-ffc1-59d1-89f5-a5abdf200635","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27361c81-c185-5b67-b396-0305d0519609","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45051d9e-ec60-5c2c-b5ba-3144fa01ed3b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4e570021-eea5-51d7-a0b9-52d2862efb98","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"259f8083-da67-544d-b6f7-dbb776d27e96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4c25a2fe-3c87-5ac4-b4c3-7f8e41ff3c06","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"357337fc-eefc-5ff8-84bf-cc4e15f9a2da","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ccf8ee4f-04be-5069-b7da-9654741f33a3","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d4547749-0ab6-4eab-9355-3219437403bb --><h3>Previous changes</h3><!-- end field d4547749-0ab6-4eab-9355-3219437403bb -->","summary":null,"htmlStringContent":"<!-- begin item 02d782e0-4a2e-49ba-bb5a-a4ac856f4ab4 --><!-- begin field c2fb1772-f239-45b6-b46b-296f2d876d14 --><p><strong>February to March 2016</strong> — reviewed. A literature search was conducted in February 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>May 2014</strong> — minor update. A link to prescriptions for topical corticosteroids has been removed and some text inserted which gives examples of mildly potent and moderately potent corticosteroids.</p><p><strong>September to December 2010</strong> — this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field c2fb1772-f239-45b6-b46b-296f2d876d14 --><!-- end item 02d782e0-4a2e-49ba-bb5a-a4ac856f4ab4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}